Dr. Timos Papagatsias’ Post

Thoughts on this? >> EMA's CHMP recommends 10 new drugs as Pierre Fabre overactive bladder med wins approval >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #pharmaceutical #biotech #productmarketing

The nasal delivery market is set to increase to US$75.7B by 2030. some possible reasons for this could be an Increasing acceptance that the nasal route offers the potential for local, systemic and direct to brain delivery whilst avoiding first pass metabolism and Patient preference and the attractiveness of self administration make it an ideal alternative to injectable dosage forms. #nasal #nasalformulations #CDMO #RDD2024

Thoughts on this? >> Merck touts updated 21-valent pneumococcal data weeks ahead of FDA decision >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #pharmaceutical #biotech #healthcare

Ginsenoside Rg5 as an anticancer drug: a comprehensive review on mechanisms, structure–activity relationship, and prospects for clinical advancement.  Our latest  article published in “Pharmacological Report”   is now available online @ https://lnkd.in/ebyfAura  

Thoughts on this? >> Neurocrine gets FDA approval in rare adrenal gland condition >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #healthcare #pharma #pharmaceutical

Thoughts on this? >> Novo Nordisk's oral amycretin could lead to more weight loss beyond 12 weeks, according to early-stage trial >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #biotech #productmarketing #pharma

AbbVie’s #Humira has long dominated the biosimilar market, but recent data suggests a shift is imminent with a decrease in market share to 82%. Sandoz's #Hyrimoz, a key player, has seen significant gains under the Cordavis co-label, recording a surge in prescriptions after CVS Health Caremark's move to exclude branded Humira from commercial formularies in April. IQVIA data indicates that 82% of Humira biosimilar prescriptions were for Hyrimoz by the end of April, propelling Sandoz to a 6% sales growth in the first quarter. On the other hand, AbbVie's collaboration with Cordavis has resulted in a joint Humira formulation, capturing around 25% of the Cordavis-labelled products market, as per Samsung Bioepis' findings. Meanwhile, Boehringer Ingelheim's #Cyltezo, competing with Humira, faced challenges with only 1,487 prescriptions since its July 2023 launch, compared to Humira's 2.8 million prescriptions during the same period. The delayed uptake led to layoffs within Boehringer's customer-facing team, prompting a shift to a hybrid approach. As AbbVie prepares to transition focus to newer immunology medications like #Skyrizi and #Rinvoq to counter Humira's declining sales – dropping from a record $21.2 billion to $14.4 billion last year – the pharma landscape is evolving rapidly. Skyrizi's recent $2 billion quarterly sales almost matched Humira, which experienced a 40% sales decline in the first quarter. The pharmaceutical market is witnessing dynamic shifts and strategic maneuvers as key players navigate the evolving landscape. ------------- Stay tuned for more insights on PharmaTell Studio or read more on our blog: https://lnkd.in/gTtPWGMk

Thoughts on this? >> Neurocrine gets FDA approval in rare adrenal gland condition >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #biotech #pharma #pharmaceutical

Thoughts on this? >> Lykos takes another hit as ICER lays out 'insufficient' evidence for MDMA-based treatment >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #productmarketing #pharma #pharmaceutical

Thoughts on this? >> Trade group tells FDA that semaglutide is not too 'complex' for compounding >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #productmarketing #pharmaceutical #pharma